SARS-CoV-2UPam-based TLR2

Giulia Castello1, Marjolein M E Isendoorn2, Marcel Camps1

  • 1Department of Immunology, Leiden University Medical Center, Albinusdreef 2, Leiden 2333 ZA, The Netherlands.

Bioconjugate chemistry
|December 31, 2025
PubMed
概括

新的合成长 (SLP) 疫苗与托尔样受体2 (TLR2) 激动剂相结合,对SARS-CoV-2免疫力显示出希望. 纯粹的UPam结合剂增强了T细胞和B细胞的反应,这表明疫苗有潜在的持久疗效.